{"disease":{"id":"gastric-cancer-metastatic","name":"gastric cancer metastatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06957678","title":"AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT06342427","title":"Stomach Cancer Exosome-based Detection","phase":"","overall_status":"COMPLETED","enrollment_count":809,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05714124","title":"Liver Embolization Approaches for Tumor Management","phase":"","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06177041","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","has_results":false},{"nct_id":"NCT05489211","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03222258","title":"Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05677490","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":382,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06902545","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":377,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT05075993","title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04248452","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":314,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06203600","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03829501","title":"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":222,"lead_sponsor_name":"Kymab Limited","has_results":true},{"nct_id":"NCT03629691","title":"Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib","phase":"","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"The Affiliated Hospital of Qingdao University","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06346197","title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT04492488","title":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":129,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false},{"nct_id":"NCT04660760","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT06702683","title":"The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Lin Liu","has_results":false},{"nct_id":"NCT06614751","title":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Danatlas Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06730373","title":"First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT05198856","title":"Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":106,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT06962137","title":"Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06730581","title":"Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Beijing Biostar Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03409848","title":"Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03597581","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT03823144","title":"Intravital Microscopy in Human Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06668454","title":"Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)","phase":"NA","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07392346","title":"Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Dai, Guanghai","has_results":false},{"nct_id":"NCT04065139","title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03129139","title":"A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":66,"lead_sponsor_name":"Minneamrita Therapeutics LLC","has_results":false},{"nct_id":"NCT04920747","title":"Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT07149090","title":"Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":61,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT04739202","title":"Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05188209","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false},{"nct_id":"NCT06121700","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03588533","title":"Herzuma-capecitabine/Cisplatin for Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Sung Yong Oh","has_results":false},{"nct_id":"NCT06427252","title":"The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04329494","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06364410","title":"Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04510064","title":"Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06341595","title":"Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06251973","title":"A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04550494","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}